Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) and Altamira Therapeutics (NASDAQ:CYTO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.
Valuation & Earnings
This table compares Lipella Pharmaceuticals and Altamira Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lipella Pharmaceuticals | $450,000.00 | 7.61 | -$4.62 million | ($4.25) | -0.67 |
| Altamira Therapeutics | $320,000.00 | 3.19 | -$4.31 million | N/A | N/A |
Altamira Therapeutics has lower revenue, but higher earnings than Lipella Pharmaceuticals.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipella Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Altamira Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Lipella Pharmaceuticals currently has a consensus price target of $16.00, suggesting a potential upside of 465.37%. Given Lipella Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Lipella Pharmaceuticals is more favorable than Altamira Therapeutics.
Insider & Institutional Ownership
74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 1.9% of Altamira Therapeutics shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 13.0% of Altamira Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Lipella Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Altamira Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Profitability
This table compares Lipella Pharmaceuticals and Altamira Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipella Pharmaceuticals | -882.82% | -192.33% | -154.24% |
| Altamira Therapeutics | N/A | N/A | N/A |
Summary
Lipella Pharmaceuticals beats Altamira Therapeutics on 7 of the 12 factors compared between the two stocks.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
About Altamira Therapeutics
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
